GTX-102
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angelman Syndrome
Conditions
Angelman Syndrome
Trial Timeline
Feb 24, 2020 → Jan 8, 2025
NCT ID
NCT04259281About GTX-102
GTX-102 is a phase 1/2 stage product being developed by Ultragenyx Pharmaceutical for Angelman Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04259281. Target conditions include Angelman Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07157254 | Phase 2 | Recruiting |
| NCT06617429 | Phase 3 | Active |
| NCT06415344 | Phase 3 | Recruiting |
| NCT04259281 | Phase 1/2 | Completed |
Competing Products
9 competing products in Angelman Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RO7248824 | Roche | Phase 1 | 33 |
| RO7248824 | Roche | Phase 1 | 33 |
| Alogabat | Roche | Phase 2 | 52 |
| ION582 | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| ION582 + Placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 | 47 |